Literature DB >> 20303483

Live babies born per oocyte retrieved in a subpopulation of oocyte donors with repetitive reproductive success.

J Ryan Martin1, Jason G Bromer, Denny Sakkas, Pasquale Patrizio.   

Abstract

OBJECTIVE: To investigate the oocyte-to-baby rate when controlled ovarian stimulation was performed on a highly successful donor population and to evaluate whether they produce a higher proportion of reproductively competent oocytes compared with standard donors.
DESIGN: Retrospective analysis of clinical and embryological database.
SETTING: University center. PATIENT(S): A total of 191 oocyte donation cycles were analyzed from 53 donors (28 best-prognosis donors and 23 standard donors). INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Total number of oocytes collected, the number of embryos transferable (fresh and frozen). and corresponding oocyte to live baby born (LBB) rates. In patients with remaining frozen embryos, the final LBB rate was estimated according to our reported rates. RESULT(S): A total of 130 oocyte retrievals from the best-prognosis donors yielded 2,470 oocytes. The total LBB per oocyte retrieved and LBB per embryo transferred was 7.3% and 24.6%, respectively. A total of 61 oocyte retrievals from the standard donors yielded 1,044 oocytes. The total LBB per oocyte and LBB per embryo transferred was 5.0% and 16.6%, respectively. This is significantly different from the best-prognosis donor group. Success rates were also analyzed after grouping donors based on the number of oocytes retrieved per cycle. In the best-prognosis group, the oocyte use rate increased significantly when fewer oocytes were retrieved, whereas the oocyte-to-baby rate was similar regardless of the number of oocytes for the standard donor group. CONCLUSION(S): This retrospective analysis revealed the existence of a subset of good-prognosis donors who produce a higher oocyte-to-baby rate that is indicative of a more biologically efficient reproductive system. Their identification, albeit a posteriori, has clinical implications for safety, by reducing ovarian hyperstimulation syndrome and multiple pregnancies, as well as for assisted reproductive technology success.
Copyright © 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20303483     DOI: 10.1016/j.fertnstert.2010.02.004

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  11 in total

1.  Improving IVF: is there a limit to our ability to manipulate human biology?

Authors:  Pasquale Patrizio; Sherman Silber
Journal:  J Assist Reprod Genet       Date:  2016-10-28       Impact factor: 3.412

2.  Educating an oocyte-the complex dialogue between mentor and mentee.

Authors:  David F Albertini
Journal:  J Assist Reprod Genet       Date:  2017-09       Impact factor: 3.412

3.  Comparison of the development of human embryos cultured in either an EmbryoScope or benchtop incubator.

Authors:  R Sciorio; J K Thong; S J Pickering
Journal:  J Assist Reprod Genet       Date:  2017-12-15       Impact factor: 3.412

4.  The total pregnancy potential per oocyte aspiration after assisted reproduction-in how many cycles are biologically competent oocytes available?

Authors:  J G Lemmen; N M Rodríguez; L D Andreasen; A Loft; S Ziebe
Journal:  J Assist Reprod Genet       Date:  2016-04-06       Impact factor: 3.357

5.  Mild stimulation approach for In Vitro Fertilization treatment: Retrospective data from one Danish Centre.

Authors:  G Almind; E Faerch; F Lindenberg; S Lindenberg
Journal:  Facts Views Vis Obgyn       Date:  2018-06

6.  A paternal effect of MTHFR SNPs on gametes and embryos should not be overlooked: case reports.

Authors:  Laetitia Jacquesson-Fournols; Silvia Alvarez; Marc Cohen; Patrice Clement; Yves Menezo
Journal:  J Assist Reprod Genet       Date:  2019-05-22       Impact factor: 3.412

7.  The Effect of Dose Adjustments in a Subsequent Cycle of Women With Suboptimal Response Following Conventional Ovarian Stimulation.

Authors:  Panagiotis Drakopoulos; Samuel Santos-Ribeiro; Ernesto Bosch; Juan Garcia-Velasco; Christophe Blockeel; Alessia Romito; Herman Tournaye; Nikolaos P Polyzos
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-23       Impact factor: 5.555

8.  Individualized ovarian stimulation in IVF/ICSI treatment: it is time to stop using high FSH doses in predicted low responders.

Authors:  Jori A Leijdekkers; Helen L Torrance; Nienke E Schouten; Theodora C van Tilborg; Simone C Oudshoorn; Ben Willem J Mol; Marinus J C Eijkemans; Frank J M Broekmans
Journal:  Hum Reprod       Date:  2020-09-01       Impact factor: 6.918

9.  The Presence of Immature GV- Stage Oocytes during IVF/ICSI Is a Marker of Poor Oocyte Quality: A Pilot Study.

Authors:  Pia Astbury; Goutham N Subramanian; Jessica Greaney; Chris Roling; Jacqui Irving; Hayden A Homer
Journal:  Med Sci (Basel)       Date:  2020-01-16

10.  Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus.

Authors:  Raoul Orvieto; Christos A Venetis; Human M Fatemi; Thomas D'Hooghe; Robert Fischer; Yulia Koloda; Marcos Horton; Michael Grynberg; Salvatore Longobardi; Sandro C Esteves; Sesh K Sunkara; Yuan Li; Carlo Alviggi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-10       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.